Positron Emission Tomography for Nine Cancers (Bladder, Brain, Cervical, Kidney, Ovarian, Pancreatic, Prostate, Small Cell Lung, Testicular). Technology Assessment Program

摘要

The University of Alberta Evidence-based Practice Center (UAEPC) reviewed and synthesized the published literature on the use of 18FDG-PET in the assessment and treatment of nine types of cancer with respect to the following clinical situations: diagnosis, staging, restaging, and monitoring response to treatment. The research questions were organized under four key questions: (1) 18FDG-PET and 18FDG-PET/CT diagnostic test performance; (2) Diagnostic thinking impact of 18FDG-PET and 18FDG-PET/CT; (3) 18FDG-PET and 18FDG-PET/CT as part of a management strategy; and (4) Cost-effectiveness of 18FDG-PET and 18FDG-PET/CT. Positron emission tomography (PET) is a form of nuclear medicine imaging that detects and establishes metabolic abnormalities in tissue. Compared to structural imaging techniques (X-ray, computed tomography (CT), and magnetic resonance imaging (MRI)), 18FDG-PET is considered a potentially major advancement in clinical practice because it may provide information about the behavior of tumors in addition to the anatomic extent and thus can provide evidence to guide therapeutic choices.